Search
Letermovir
go.drugbank.com/drugs/DB12070ApprovedInvestigationalLetermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients. … [L1021] It is the first of a new class of CMV anti-infectives called DNA terminase complex inhibitors.[A31290] Letermovir has recieved both priority and orphan drug status from the FDA.
Palbociclib
go.drugbank.com/drugs/DB09073ApprovedInvestigationalPalbociclib is a piperazine pyridopyrimidine[A176792] that acts in the cell cycle machinery. … It is a second generation cyclin-dependent kinase inhibitor[A176798] selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexTezacaftor
go.drugbank.com/drugs/DB11712ApprovedInvestigationalTezacaftor is a drug of the cystic fibrosis transmembrane conductance regulator (CFTR) corrector class. … Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes.
Perampanel
go.drugbank.com/drugs/DB08883ApprovedInvestigationalPerampanel is a noncompetitive AMPA glutamate receptor antagonist. … It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures.
Ivosidenib
go.drugbank.com/drugs/DB14568ApprovedInvestigationalIvosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. … The drug is only effective in patients with a susceptible IDH1 mutation.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexLeflunomide
go.drugbank.com/drugs/DB01097ApprovedInvestigationalLeflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. … Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous.
Synonyms: 4-ISOXAZOLECARBOXAMIDE, 5-METHYL-N-(4-(TRIFLUOROMETHYL)PHENYL)-, 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamideProducts: LEFLUNOMID 1A PHARMA 10MG, LEFLUNOMID 1A PHARMA 20MGFavezelimab
go.drugbank.com/drugs/DB16729InvestigationalFavezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A
Colchicine
go.drugbank.com/drugs/DB01394ApprovedInvestigationalColchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus."[A183611] Its use was first approved by the FDA in 1961. … [L47591] It has also been investigated in other inflammatory and fibrotic conditions.[A183602]
Categories: Preparations With No Effect on Uric Acid MetabolismProducts: L-CISINNazartinib
go.drugbank.com/drugs/DB16250InvestigationalNazartinib is under investigation in clinical trial NCT03529084 (Phase III Study of Nazartinib (EGF816) Versus Erlotinib/gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating
Crotamiton
go.drugbank.com/drugs/DB00265ApprovedCrotamiton is a scabicidal and antipruritic agent available as a cream or lotion for topical use only. It is a colorless to slightly yellowish oil, having a faint amine-like odor. … It is miscible with alcohol and with methanol.
Categories: Compounds used in a research, industrial, or household settingProducts: A-Bite Cream, CROTAMITON LOCION AL 10 %